The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Amryt Pharma plc Common 03217L106 28,824 2,668,843 SH   SOLE   2,668,843 0 0
Dyne Therapeutics, Inc. Common 26818M108 58,871 4,951,303 SH   SOLE   4,951,303 0 0
Entrada Therapeutics, Inc. Common 29384C108 75,769 4,425,784 SH   SOLE   4,425,784 0 0
Harpoon Therapeutics, Inc. Common 41358P106 23,642 3,131,388 SH   SOLE   3,131,388 0 0
iTeos Therapeutics, Inc. Common 46565G104 134,347 2,885,470 SH   SOLE   2,885,470 0 0
Oncorus, Inc. Common 68236R103 15,017 2,849,464 SH   SOLE   2,849,464 0 0
Repare Therapeutics, Inc. Common 760273102 47,297 2,242,636 SH   SOLE   2,242,636 0 0
Rhythm Pharmaceuticals, Inc. Common 76243J105 9,074 909,258 SH   SOLE   909,258 0 0
TCR2 Therapeutics, Inc. Common 87808K106 18,877 4,050,865 SH   SOLE   4,050,865 0 0
Werewolf Therapeutics, Inc. Common 95075A107 51,024 4,284,172 SH   SOLE   4,284,172 0 0